Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue
M Briskin, D Winsor-Hines, A Shyjan, N Cochran, S Bloom, J Wilson, L M McEvoy, E C Butcher, N Kassam, C R Mackay, W Newman, D J Ringler, M Briskin, D Winsor-Hines, A Shyjan, N Cochran, S Bloom, J Wilson, L M McEvoy, E C Butcher, N Kassam, C R Mackay, W Newman, D J Ringler
Abstract
Lymphocyte homing to normal tissues and recruitment to inflammatory tissue sites are controlled, in part, by the selective expression of chemokines, pro-inflammatory cytokines and mediators, and various adhesion proteins and molecules. In the mouse, mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is selectively expressed on endothelium of high endothelial venules in gut and gut-associated lymphoid tissue. By interaction with its integrin ligand, alpha 4 beta 7, lymphocytes presumed to be involved in mucosal immunity are selectively recruited to these intestinal sites. After generating monoclonal antibodies against a murine cell line expressing recombinant human MAdCAM-1, we qualitatively and semiquantitatively assessed MAdCAM-1 expression in human tissue sections from various normal and inflammatory disorders. We found that human MAdCAM-1, as in the mouse, is expressed in a tissue-selective manner. In normal tissues, MAdCAM-1 is constitutively expressed to endothelium of venules of intestinal lamina propria. Interestingly, using computer-assisted morphometric analysis, the proportion of venular endothelium within lamina propria that expresses MAdCAM-1 is increased, compared with normal tissues, at inflammatory foci associated with ulcerative colitis and Crohn's disease. Moreover, for the most part, MAdCAM-1 is not detected in the majority of normal or inflamed extra-intestinal tissues, including those with mucosal surfaces. These results are consistent with a role, as originally defined in the mouse, for human MAdCAM-1 in the localization of alpha 4 beta 7+ lymphocytes in the gastrointestinal tract and associated lymphoid tissue. As such, the pathway defined by MAdCAM-1/alpha 4 beta 7 may be a relevant tissue-specific therapeutic target for the modulation of inflammatory bowel disease activity.
References
- Annu Rev Immunol. 1992;10:561-91
- J Immunol. 1994 Jun 15;152(12):5969-78
- Cell. 1993 Jul 16;74(1):185-95
- J Immunol. 1993 Jul 15;151(2):717-29
- J Clin Invest. 1993 Nov;92(5):2509-15
- J Immunol. 1993 Nov 15;151(10):5239-50
- Cell. 1994 Jan 28;76(2):301-14
- Lab Invest. 1994 Feb;70(2):163-75
- J Immunol. 1994 Apr 1;152(7):3282-93
- J Clin Invest. 1994 Apr;93(4):1554-63
- J Immunol. 1994 Jul 15;153(2):517-28
- J Immunol. 1994 Nov 1;153(9):3847-61
- J Exp Med. 1995 Jan 1;181(1):137-49
- Eur J Immunol. 1980 Jul;10(7):556-61
- Lab Invest. 1987 Mar;56(3):313-20
- Am J Pathol. 1987 Feb;126(2):199-207
- Nature. 1988 Jan 7;331(6151):41-6
- J Cell Biol. 1988 Nov;107(5):1853-62
- Clin Immunol Immunopathol. 1988 Dec;49(3):349-64
- Nature. 1989 Jan 12;337(6203):179-81
- Am J Pathol. 1989 Feb;134(2):373-83
- Am J Pathol. 1991 Feb;138(2):385-93
- Immunology. 1991 Apr;72(4):520-5
- Cell. 1991 Dec 20;67(6):1033-6
- Cell. 1995 Feb 10;80(3):413-22
- Immunity. 1995 Jul;3(1):99-108
- Am J Pathol. 1995 Sep;147(3):763-71
- J Immunol. 1996 Apr 15;156(8):2851-7
- J Immunol. 1996 May 15;156(10):3727-36
- Am J Pathol. 1996 Jun;148(6):1819-38
- J Exp Med. 1996 Jun 1;183(6):2437-48
- J Immunol. 1996 Sep 15;157(6):2488-97
- Gastroenterology. 1996 Nov;111(5):1373-80
- J Immunol. 1997 Mar 1;158(5):2099-106
- Annu Rev Immunol. 1993;11:767-804
Source: PubMed